| abstract |
Described is the use of a selective iGluR5 receptor antagonist for the manufacture of a medicament for treating migraine wherein the selective iGluR5 is 3S, 4aR, 6S, 8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid. More generally is described the use of a iGluR5 receptor antagonist compound of Formula I, wherein R1 and R2 are independently H, alkyl, alkenyl, alkylaryl, alkyl-cycloalkyl, alkyl-N,N-dialkylamine, alkyl-pyrrolidine, alkyl-piperidine, or alkyl-morpholine. |